Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Morphosys AG (GB:0NDV)
LSE:0NDV
Morphosys (0NDV) Share Price & Analysis
1 Followers
0NDV Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€14.56 - €68.35
Previous Close€66.2
Volume20.39K
Average Volume (3M)178.91K
Market Cap
€2.49B
Enterprise Value€2.59B
Total Cash (Recent Filing)€158.50M
Total Debt (Recent Filing)€256.45M
Price to Earnings (P/E)-11.7
Beta0.59
Next Earnings
Aug 07, 2024EPS Estimate
-€2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.68
Shares Outstanding34,160,673
10 Day Avg. Volume16,390
30 Day Avg. Volume178,907
Standard Deviation0.11
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.73
Price to Sales (P/S)15.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€58.75Price Target Upside-10.83% Downside
Rating ConsensusHold
Number of Analyst Covering5
Morphosys News
PremiumPre-Earnings
Is 0NDV a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
AcquisitionMOR expects the acquisition by Novartis to close, which could streamline regulatory processes and benefit the company's strategic positioning.
Financial StabilityThe company reported sufficient cash reserves expected to provide financial runway through early 2026, ensuring stability in the medium term.
Product PipelineThe company plans to submit filings for regulatory approvals for pelabresib, showing progress in its product pipeline.
Bears Say
Commercial PotentialClinicians may remain cautious about adding pelabresib to Jakafi until long-term safety is better understood, impacting commercial potential.
Regulatory ConcernsA warning letter was issued by the FDA to physicians involved in the MANIFEST-2 trial, raising concerns about the trial's outcomes and potential implications for the deal.
Safety IssuesThe rate of AML transformation in the pela + rux arm of the trial appears higher than in other studies and the disease's natural course, which could raise safety concerns.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.54% Insiders
4.45% Mutual Funds
4.75% Other Institutional Investors
89.26% Public Companies and
Individual Investors
0NDV FAQ
What was Morphosys AG’s price range in the past 12 months?
Morphosys AG lowest share price was €14.55 and its highest was €68.35 in the past 12 months.
What is Morphosys AG’s market cap?
Currently, no data Available
When is Morphosys AG’s upcoming earnings report date?
Morphosys AG’s upcoming earnings report date is Aug 07, 2024 which is in 96 days.
How were Morphosys AG’s earnings last quarter?
Morphosys AG released its earnings results on Apr 29, 2024. The company reported -€8.27 earnings per share for the quarter, missing the consensus estimate of -€1.129 by -€7.141.
Is Morphosys AG overvalued?
According to Wall Street analysts Morphosys AG’s price is currently Overvalued.
Does Morphosys AG pay dividends?
Morphosys AG does not currently pay dividends.
What is Morphosys AG’s EPS estimate?
Morphosys AG’s EPS estimate is -€2.03.
How many shares outstanding does Morphosys AG have?
Morphosys AG has 37,716,423 shares outstanding.
What happened to Morphosys AG’s price movement after its last earnings report?
Morphosys AG reported an EPS of -€8.27 in its last earnings report, missing expectations of -€1.129. Following the earnings report the stock price went up 1.223%.
Which hedge fund is a major shareholder of Morphosys AG?
Currently, no hedge funds are holding shares in GB:0NDV
---
Morphosys Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€58.75 (-10.83% Downside)
€58.75 (-10.83% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
246.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.85%
Trailing 12-Months
Company Description
Morphosys AG
MorphoSys AG is a biotechnology company that develops therapeutic antibodies. The company reports two business segments: partnered discovery and proprietary development. Its partnered discovery segment applies the research, development, and optimization of antibody-drug candidates in partnerships with pharmaceutical and biotechnology companies. MorphoSys' profits in this segment stem from successful programs via milestone payments and potential royalties on product sales. In its proprietary development segment, the company develops antibodies that concentrate on inflammatory and autoimmune diseases, as well as cancer and infectious diseases.
---
0NDV Stock 12 Months Forecast
Average Price Target
€58.75
▼(-10.83% Downside)
Technical Analysis
Best Analysts Covering 0NDV
1 Year
1 Year Success Rate
15/32 ratings generated profit
1 Year Average Return
+12.94%
reiterated a buy rating 3 months ago
Copying James Gordon's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +12.94% per trade.
---